|Description||This active molecular is a selective non-peptide Endothelin ETA receptor antagonist. It displays more than 1000-fold selectivity over ETB receptors (Ki of 48 nM for ETA receptors and >50 μM for ETB). BMS 182874 displays ET-1 inhibitory efficacy in vivo and vitro and it also inhibits ET-1-induced longitudinal muscle contraction in vitro. In 2006, BMS 182874 for coronary disorders and hypertension were discontinued in USA.|
|Appearance||White to beige powder|
|Synonyms||BMS 182874; BMS-182874; BMS182874; BMS 182874 HCl; BMS 182874 hydrochloride; 5-(dimethylamino)-N-(3,4-dimethylisoxazol-5-yl)naphthalene-1-sulfonamide hydrochloride|
|Solubility||Soluble in DMSO|
|Application||coronary disorders and hypertension|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator:Bristol-Myers Squibb|
Enrasentan, an indene derivative, has been found to be an endothelin receptor antagonist that was once studied in reperfusion injury and heart failure therapy.
SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.
Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.
T-0201 has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonar...
[Ala1,3,11,15]-Endothelin is a selective ETB endothelin receptor agonist (IC50 = 0.33 and 2200 nM for displacing [125I]-ET-1 from ETB and ETA receptors, respect...
Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the treatment of pulmonary arterial hyperten...
Sarafotoxin S6c is a highly selective ETB endothelin receptor agonist (Ki = 0.29 and 28000 nM at ETB and ETA receptors, respectively).
A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmente...